Hair Loss in the Dermatology Office: An Update on Alopecia Areata
INTRODUCTION
Hair loss is a frequent clinical complaint encountered by dermatologists,
and alopecia areata (AA)-induced hair loss is
responsible for 0.7 to 3.8% of dermatology clinic visits.1 Alopecia
areata is characterized by chronic yet reversible, non-scarring
hair loss. It is postulated to be an autoimmune process that targets
the hair follicle, although the pathogenesis is incompletely
understood.1-3 This article summarizes the epidemiologic and
clinical features of AA, outlines our current understanding of its
pathogenesis, and reviews therapeutic options for this condition.
Epidemiology
Alopecia areata affects patients of all ages and ethnicities with an
equal sex distribution.1,2,4 Approximately 0.1-0.2% of the United
States population is affected5; there is a lifetime risk of about
1.7%.6,7 Roughly 60% of patients present before age 20, and a
family history of AA is seen in about 20% of patients.2
Clinical Presentation
Alopecia areata can affect any hair-bearing epidermal site, but involves
the scalp in approximately 90%.1,2 Classic AA lesions are
well-demarcated, ovoid patches with no overt epidermal change.
Patients typically present with a spontaneous, asymptomatic hair
loss in a solitary nummular patch. Alternate presentations include
multiple alopecic patches or rapid progression to complete loss
of scalp/facial hair (alopecia totalis) or body hair (alopecia universalis).
Rarer hair loss variants include reticular, ophiasis, ophiasis
inversus, and diffuse thinning over the entire scalp.1,8 Associated
clinical findings that aid diagnosis include “exclamation markâ€
hairs, “cadaver†hairs, red lunulae, rows of nail pitting or trachyonychia,
and the presence of other autoimmune disorders.1,8,9
Etiology
Genetics
Alopecia areata is considered a polygenic disorder with variable
phenotypes in which several major genes dictate susceptibility
to disease and numerous minor genes modulate phenotype.10
The latter may explain the variable disease severity seen in
AA: some patients experience one patch of alopecia, and others
demonstrate total body hair loss.10 The genetic component
of alopecia areata is supported by several findings: there is a
higher incidence of AA in genetically related individuals:7 up
to 28% of patients report at least one affected family member,1 monozygotic twins have exhibited similar times of onset and
patterns of hair loss,1,11,12 and several human leukocyte antigen
(HLA) alleles are associated with AA.1,7 Finally, genes on chromosome
21 may be implicated in AA susceptibility because
there is an association with both Down syndrome and Autoimmune
polyendocrinopathy syndrome type 1, two conditions
owing to genetic defects on this chromosome.7
Environment
The 42% - 55% concordance rate in monozygotic twins not only
suggests a genetic etiology of AA, but it also implicates environmental
influences in the pathogenesis of this condition.13,14
While the inheritance of specific alleles may provide innate
susceptibility to developing AA, environmental factors likely
trigger disease onset and modify the pattern and extent of hair
loss, chronicity of disease, and resistance to treatment.1,7,10 Hormonal
fluctuation,1 infection,15-17 vaccinations,18,19 and diet1,20
have all been cited as possible triggers for AA, though additional
research is warranted to clarify these associations. The
role that psychosocial stressors play on disease onset and relapse
is largely uncharacterized. Life stressors may instigate AA
onset and modify disease course, yet evidence is circumstantial
and clinical studies are inconclusive: some studies found
no correlation between the onset of hair loss and stressful life
events,21-23 whereas others affirmed that stressful life events
preceded disease onset and relapse.4,22,24,25,26
Pathophysiology
The normal hair cycle has four distinct phases: anagen, catagen,
telogen and exogen (Figure 1). AA is characterized by abnormal
hair cycling: T lymphocytes attack anagen hair follicles, which are
subsequently maintained in a dystrophic state. Such dystrophy
precludes hair production of appropriate integrity or size, and the
shaft can no longer be firmly anchored in the hair canal, resulting
in rapid hair shedding.1,8 Other perturbations in the hair cycle are
seen: the follicle can be prematurely ushered into telogen and then
proceed in a shortened cycle in which it is repeatedly arrested in
early anagen.22 In chronic AA, follicles can persist in a prolonged
telogen phase without cycling back to the anagen growth phase.1,2
Unlike scarring alopecias, the hair follicle stems cells are not destroyed
in AA. Rather, the follicles are effectively switched off: they
remain arrested in a hibernation-like state and can resume normal
growth after a period of months to years.2,8
The pathophysiology of this process is not fully elucidated, but
available evidence suggests a T cell-mediated autoimmune
process directed at the hair follicle.1,8,10,15 Normally, the hair follicle
creates a milieu of immunologic privilege, ie, it is protected
from immune surveillance by autoreactive T cells. Failure of this
immune privilege and development of autoantibodies against
a hair follicle antigen is theorized in the pathogenesis of AA
(Figure 2). However, the antigens responsible for initiating this
autoimmune reaction remain unidentified.7,8,17